Medaer R, Stinissen P, Truyen L, Raus J, Zhang J
Multiple Sclerosis Research and Immunology Unit, Dr L Willems Instituut, Diepenbeek, Belgium.
Lancet. 1995 Sep 23;346(8978):807-8. doi: 10.1016/s0140-6736(95)91622-9.
In a pilot trial, eight patients with multiple sclerosis were matched to control patients and received T-cell vaccination with irradiated T cells reactive to myelin basic protein (MBP) to deplete circulating MBP-reactive T cells. In the 2 years before and after vaccination, exacerbations decreased in five vaccinated patients (numbers 1, 2, 6-8) with relapsing-remitting disease from sixteen to three, respectively, and from twelve to ten in their matched controls. Magnetic resonance imaging showed a mean 8.0% increase in brain lesion size in the vaccinated patients compared with a 39.5% increase in the controls. Lesions and/or relapses worsened in three cases after vaccination in association with reappearance of circulating MBP-reactive T cells.
在一项试点试验中,8名多发性硬化症患者与对照患者进行匹配,并接受了用对髓鞘碱性蛋白(MBP)有反应的经辐射的T细胞进行的T细胞疫苗接种,以耗尽循环中对MBP有反应的T细胞。在接种疫苗前后的2年里,5名复发缓解型疾病的接种疫苗患者(编号1、2、6 - 8)的病情加重次数分别从16次降至3次,而其匹配的对照患者则从12次降至10次。磁共振成像显示,接种疫苗的患者脑病变大小平均增加了8.0%,而对照患者增加了39.5%。3例患者在接种疫苗后病情加重和/或复发,同时循环中对MBP有反应的T细胞再次出现。